Medincell Publishes its Consolidated Half-Year Financial Results (April 1st , 2025 – September 30, 2025)
December 9, 2025
Next PostMedincell’s Partner Teva Pharmaceuticals Announces the New Drug Application Submission to U.S. FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749 / mdc-TJK) for the Once-Monthly Treatment of Schizophrenia in Adults
